- Poster presentation
- Open Access
Bortezomib sensitizes human glioblastoma stem cells to adoptive natural killer cell cytotoxicity
© Grossenbacher et al. 2015
Published: 4 November 2015
Glioblastoma multiforme (GBM) is the most common primary malignant human brain tumor and one of the most lethal of all cancer types. Despite the introduction of numerous non-surgical therapies for GBM, clinically relevant responses to treatment are rarely durable. Small populations of stem cells residing within GBM tumors have the ability to differentiate into diverse cell types in vitro and in vivo, and form new heterogeneous tumors in immune compromised mice. These cells have been found to express high amounts of aldehyde dehydrogenase (ALDH), can resist radiation therapy and chemotherapy, and represent an important target in the advancement of glioblastoma treatment.
We and others have identified natural killer (NK) cells as having an inherent ability to kill human GBM stem cells (GSCs), through the recognition of specific activating proteins on the GSC surface which facilitate NK cell, activation, recognition, and killing. Here we found that primary human GBMs contain a small population of cells (4-14%) expressing high amounts of the stem cell associated protein ALDH which can be selectively killed by activated human NK cells.
Bortezomib, a small molecule proteasome inhibitor, has previously been found to sensitize human and mouse tumor cells to TRAIL and/or NK cell-mediated killing through the expression of apoptosis-inducing death receptors such as DR5. Additionally bortezomib has proved to have some anecdotal efficacy for adults with recurrent gliomas in early clinical trials. In this study we found that bortezomib significantly improves activated human NK cell killing of ALDHbright human GSCs. Additionally we found that in vitro bortezomib treatment significantly enhances human GSC expression of Fas and DR5, while having a much smaller effect on ALDHdim cells. Lastly, utilizing an orthotopic xenograft model of human GBM in the brains of NSG mice, we found that the administration of bortezomib prior to intracranial human activated NK cell infusions led to significant increases in tumor growth delay compared to either bortezomib or NK cells alone.
These data provide preclinical rational for the combined use of bortezomib and adoptive NK cell therapy for the treatment of human GBM, with the potential to kill ALDHbright GSCs.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.